Diabeta, Amglidia(glyburide)
Diabeta, Glyburide, Glynase (glyburide) is a small molecule pharmaceutical. Glyburide was first approved as Micronase on 1984-05-01. It is used to treat type 2 diabetes mellitus in the USA. The pharmaceutical is active against ATP-sensitive inward rectifier potassium channel 11. In addition, it is known to target ATP-sensitive inward rectifier potassium channel 8, cystic fibrosis transmembrane conductance regulator, and solute carrier organic anion transporter family member 2B1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Diabeta, Glyburide, Glynase (discontinued: Glyburide, Glynase, Micronase)
CombinationsGlyburide metformin (discontinued: Glucovance, Glyburide metformin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Glyburide
Glyburide
+
Metformin hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| GLUCOVANCE | Bristol Myers Squibb | N-021178 DISCN | 2000-07-31 | 3 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| glucovance | New Drug Application | 2012-04-23 |
| glyburase | 2006-09-19 | |
| glyburide | ANDA | 2025-10-31 |
| glyburide and metformin | ANDA | 2011-12-20 |
| glyburide and metformin hydrochloride | ANDA | 2025-06-16 |
| glyburide-metformin hydrochloride | ANDA | 2025-09-24 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
139 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 4 | 5 | 19 | 21 | 19 | 68 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 3 | 4 | 15 | 12 | 10 | 43 |
| Gestational diabetes | D016640 | — | O24.4 | 2 | 1 | 3 | 7 | 5 | 17 |
| Hypoglycemia | D007003 | — | E16.2 | 1 | 4 | 1 | 1 | 1 | 7 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | 2 | 2 | 1 | 5 |
| Glucose metabolism disorders | D044882 | — | — | — | — | 3 | 2 | — | 5 |
| Dyslipidemias | D050171 | — | — | — | — | 3 | 2 | — | 5 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | 1 | 2 | 4 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | 1 | 2 | 1 | 4 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 2 | 1 | 3 |
Show 14 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 12 | — | 1 | — | 2 | 15 |
| Brain edema | D001929 | EFO_1000845 | G93.6 | 1 | 2 | 2 | — | — | 3 |
| Ischemic stroke | D000083242 | — | — | 1 | 3 | 1 | — | — | 3 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 1 | 2 | — | — | 3 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 2 | — | 1 | 3 |
| Reperfusion injury | D015427 | — | — | — | — | 1 | — | 1 | 2 |
| Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | — | — | 1 | — | — | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | 1 | — | — | 1 |
| Central nervous system diseases | D002493 | — | G96.9 | — | — | 1 | — | — | 1 |
| Brain diseases | D001927 | — | G93.40 | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Traumatic brain injuries | D000070642 | — | S06 | 2 | 2 | — | — | — | 3 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | 1 | — | — | 1 | 2 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 2 | 1 | — | — | — | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 1 | — | — | — | 1 |
| Brain contusion | D000070624 | — | — | — | 1 | — | — | — | 1 |
| Malignant mesothelioma | D000086002 | — | — | — | 1 | — | — | — | 1 |
| Anthrax | D000881 | — | A22 | — | 1 | — | — | — | 1 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | 1 | — | — | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 1 | — | — | — | 1 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Angina pectoris | D000787 | EFO_0003913 | I20 | 1 | — | — | — | — | 1 |
| Myocardial reperfusion injury | D015428 | EFO_0002687 | — | 1 | — | — | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | — | — | — | — | 1 |
| Neuralgia | D009437 | EFO_0009430 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Headache | D006261 | — | R51 | — | — | — | — | 3 | 3 |
| Cerebrovascular circulation | D002560 | — | — | — | — | — | — | 2 | 2 |
| Pancreatitis | D010195 | EFO_0000278 | K85 | — | — | — | — | 1 | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 1 | 1 |
| Cerebral hemorrhage | D002543 | — | — | — | — | — | — | 1 | 1 |
| Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | — | 1 | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 1 | 1 |
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Glyburide |
| INN | glibenclamide |
| Description | Glyburide is an N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group. It has a role as a hypoglycemic agent, an anti-arrhythmia drug, an EC 2.7.1.33 (pantothenate kinase) inhibitor and an EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor. It is a N-sulfonylurea and a member of monochlorobenzenes. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 10238-21-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL472 |
| ChEBI ID | 5441 |
| PubChem CID | 3488 |
| DrugBank | DB01016 |
| UNII ID | SX6K58TVWC (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SLCO2B1
SLCO2B1
AKR1C1
AKR1C1
Organism
Homo sapiens
Gene name
SLCO2B1
Gene synonyms
KIAA0880, OATP2B1, OATPB, SLC21A9
NCBI Gene ID
Protein name
solute carrier organic anion transporter family member 2B1
Protein synonyms
OATP-B, OATP-RP2, OATP2B1, OATPRP2, Organic anion transporter B, Organic anion transporter polypeptide-related protein 2, Organic anion transporting polypeptide 2B1, solute carrier family 21 (organic anion transporter), member 9, Solute carrier family 21 member 9
Uniprot ID
Mouse ortholog
Slco2b1 (101488)
solute carrier organic anion transporter family member 2B1 (Q8BXB6)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Glyburide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Glyburide
+
Metformin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 20,607 documents
View more details
Safety
Black-box Warning
Black-box warning for: Glyburide and metformin hydrochloride, Glyburide-metformin hydrochloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,047 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use